1. A 26-week Tolerability Study of Ciclesonide Nasal Aerosol in Patients with Perennial Allergic Rhinitis
- Author
-
Holly Huang, Dale Mohar, William E. Berger, Gordon Raphael, Joseph Hinkle, Craig LaForce, and S.Y. Desai
- Subjects
Adult ,Male ,medicine.medical_specialty ,Rhinitis, Allergic, Perennial ,Ciclesonide ,Placebo ,chemistry.chemical_compound ,Double-Blind Method ,Quality of life ,Pregnenediones ,Internal medicine ,Anti-Allergic Agents ,medicine ,Humans ,Immunology and Allergy ,Adverse effect ,business.industry ,Incidence (epidemiology) ,Nasal Sprays ,General Medicine ,Middle Aged ,Metered-dose inhaler ,Otorhinolaryngology ,chemistry ,Tolerability ,Tolerability Study ,Quality of Life ,Female ,business - Abstract
Background A new, hydrofluoroalkane nasal aerosol solution formulation of ciclesonide (CIC-HFA) delivered via a metered dose inhaler is currently in clinical development for treatment of allergic rhinitis. Objective To study tolerability and quality of life following administration of CIC-HFA 74- or 148-μg doses once-daily compared with placebo in patients with perennial allergic rhinitis (PAR) over 26 weeks. Methods Patients ≥12 years of age with a ≥2 year history of PAR were randomized in a placebo-controlled, double-blind, parallel group, multicenter study to CIC-HFA 74 μg, 148 μg, or placebo QD AM for 26 weeks. Safety was assessed by monitoring treatment-emergent adverse events (TEAEs). Quality of life was assessed by using a rhinoconjunctivitis quality of life questionnaire with standardized activities (RQLQ[S]) in patients with baseline RQLQ ≥3.00. Reflective total nasal symptom scores (rTNSS) and instantaneous total nasal symptom scores (iTNSS) over 26 weeks were also evaluated. Results In this study, 1111 patients were randomized. The overall incidence of TEAEs was comparable between the treatment groups. Treatment with CIC-HFA 74- or 148-μg doses showed improvements in RQLQ[S] [least squares (LS) mean change 0.40 and 0.37, respectively from baseline, p < 0.01 versus placebo for both], rTNSS (LS mean change 0.65 and 0.52, respectively from baseline; p ≤ 0.01 versus placebo for both), and iTNSS (LS mean change 0.51 and 0.42, respectively from baseline; p < 0.05 versus placebo for both) from baseline. Conclusion In this study, once-daily treatment with CIC-HFA 74- or 148-μg doses over 26 weeks was well tolerated with comparable incidence of TEAEs between the treatment groups.
- Published
- 2012